Pharmacokinetics of diphemanil methylsulphate in neonates and in premature infants. 1996

A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D008297 Male Males
D010880 Piperidines A family of hexahydropyridines.
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018727 Muscarinic Antagonists Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antimuscarinic,Antimuscarinic Agent,Antimuscarinic Agents,Cholinergic Muscarinic Antagonist,Muscarinic Antagonist,Antimuscarinics,Cholinergic Muscarinic Antagonists,Agent, Antimuscarinic,Agents, Antimuscarinic,Antagonist, Cholinergic Muscarinic,Antagonist, Muscarinic,Antagonists, Cholinergic Muscarinic,Antagonists, Muscarinic,Muscarinic Antagonist, Cholinergic,Muscarinic Antagonists, Cholinergic
D019540 Area Under Curve A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992) AUC,Area Under Curves,Curve, Area Under,Curves, Area Under,Under Curve, Area,Under Curves, Area

Related Publications

A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
January 1993, European journal of clinical pharmacology,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
January 1992, European journal of clinical pharmacology,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
January 1994, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
March 1990, The Japanese journal of antibiotics,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
June 2002, Anesthesiology,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
January 1984, Developmental pharmacology and therapeutics,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
January 1996, European journal of clinical pharmacology,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
January 1990, Archives francaises de pediatrie,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
May 1993, Archives francaises de pediatrie,
A Pariente-Khayat, and A M Vidal, and G Cheron, and F Vauzelle-Kervroedan, and P D'Athis, and E Rey, and J B Gouyon, and C Wood, and G Olive, and G Pons
August 1995, Therapeutic drug monitoring,
Copied contents to your clipboard!